In November 2016 ProLynx was awarded a $250,000 supplement to its Phase II grant from the National Science Foundation (NSF) to support preclinical studies of its hydrogel-octreotide delivery system.
In June 2015 ProLynx was awarded TECP supplement of $141,691 to its Phase II grant from the National Science Foundation (NSF). The supplement was awarded to support in vivo imaging studies of its hydrogels as potential drug carriers for treatment of inner ear disorders.
In November 2014 ProLynx was awarded an NSF Phase II grant, entitled "Controlled drug release from and degradation of PEG-hydrogels". The grant provides nearly $742,778 of funding over two years. This follows the successful conclusion of the Phase I and IB portions of the proposal.
In 2013 Prolynx was awarded a $180,000 Phase 1 SBIR grant from the NSF to develop its hydrogel drug-delivery system.
In June 2013 Prolynx was awarded a $30,000 Phase 1B grant from NSF.
In May 2010 Prolynx was awarded a $143,958 Phase 1 SBIR grant from the NIH, entitled “Releasable site-specific attachment of macromolecules to therapeutic peptides”.
In July 2010 Prolynx was awarded a $149,958 Phase 1 SBIR grant from the NIH, entitled entitled “Releasable attachment of drugs to PEGylated dendrimers”.
In October 2010 the Company was awarded nearly $245,000 under the Qualifying Therapeutic Discovery Grants program.
Collaborations: We believe our platform can be an essential tool for R&D companies that engage in discovery and/or development of novel therapeutic peptides, proteins and small molecule therapeutics, as well as for use with mature products for life cycle management. We are seeking partnerships with pharmaceutical companies to design and prepare drug conjugates for half-life extension. When we deliver on a project, we will grant our partner a license to our technology and IP to commercialize the subject drug-conjugate.
ProLynx has concluded the following collaborations:
In April 2015 ProLynx entered into an Evaluation Agreement with Delenex to evaluate Prolynx's half-life extension technology with a single-chain antibody.
In October 2015 ProLynx entered into an Evaluation Agreement with Bayer Pharmaceuticals to evaluate Prolynx's half-life extension technology.
In July 2014 ProLynx entered into an Evaluation Agreement with GlaxoSmithKline Research & Development Limited (GSK). Pursuant to the collaboration, GSK and ProLynx will evaluate the combination of GSK biologics assets with ProLynx's controlled release technology.
In February 2014 ProLynx entered into a license agreement with a Japanese pharmaceutical company. The partner will develop ProLynx's PEG~SN-38 conjugate for use in oncology. The partner has limited Asian territorial rights and started Phase 1 studies in early 2015.
In late 2013 ProLynx entered into a collaboration with a major medical products company for the development of our hydrogels as a surgical sealant.
In late 2013 ProLynx entered into two evaluation agreements with companies evaluating our hydrogels for opthalmic delivery.
In October 2012 ProLynx entered into a relationship with Bayer HealthCare LLC. Under the terms of the arrangement, ProLynx will develop conjugates of undisclosed Bayer therapeutic molecules, the first of which is a protein. The goal is to improve the PK parameters of the drug target in a manner that would enable less frequent administration of the drug.
In late 2011 ProLynx established a relationship with TIBOTEC to evaluate the ProLynx proprietary linker technology with various TIBOTEC therapeutic compounds.
Contact us if you would like to learn more about our capabilities and/or partnering models.
Copyright © Prolynx LLC. All rights reserved